Soluble IL-1 Receptor 2 Associate with Ventricular Remodelling in ST-Elevation Myocardial

Supplementary Material

Orrem HL et al.

Soluble IL-1 receptor 2 associate with ventricular remodelling in ST-elevation myocardial infarction

SUPPLEMENTARY FIGURE

Supplementary Figure S1. Regulators of Interleukin (IL)-1 signalling.

IL-1 (IL-1α or IL-1β) binds to IL-1 receptor 1 (IL-1R1), IL-1R accessory protein (IL-1RAcP) is recruited and signaling initiated(A). IL-1 receptor antagonist (IL-1Ra) binds IL-1R1 with high specificity, but does not trigger downstream signaling(B). IL-1R2 binds IL-1, but does not initiate signalling(C). Soluble (s) IL-1R2 binds and neutralizes IL-1 with high affinity (D), while sIL-1R1 has preferential affinity for IL-1Ra (E). Soluble (s) IL-1RAcP may either inhibit formation of the signalling complex (F)or stabilize the binding of IL-1 to sIL-1R2(G).

Supplementary results

Supplementary Table S1.Correlations between soluble IL-1 regulators and measures of cardiac injury and function.

IL-1Ra / sIL-1R1 / sIL-1R2 / sIL-1RAcP
Infarct size, acute / 0.06 / 0.000 / 0.15* / -0.19**
Infarct size, 4 months / 0.08 / -0.02 / 0.09 / -0.17*
Ejection fraction, acute / -0.14 / -0.07 / -0.15* / 0.06
Ejection fraction, 4 months / -0.07 / -0.06 / -0.12 / 0.10
Area at risk / 0.07 / -0.07 / 0.12 / -0.11
Myocardial salvage / -0.03 / -0.06 / -0.10 / 0.09
LVEDVi / 0.10 / -0.02 / 0.21** / -0.04
LVESVi / 0.12 / -0.05 / 0.16* / -0.06
Peak troponin T / 0.10 / 0.01 / -0.17** / -0.17**
Peak C-reactive protein / 0.35** / 0.03 / 0.19** / -0.13
Admission NT-proBNP / 0.09 / 0.12 / -0.20** / -0.03
Symptom to PCI time / -0.03 / -0.11 / -0.06 / -0.14*

Correlations are based on plasma levels of interleukin-1 receptor antagonist (IL-1Ra), soluble (s) IL-1R1, sIL-1R2 and sIL-1R accessory protein (sIL-1RAcP) measured day 1 (median 18.3 hours after PCI) after ST-elevation myocardial infarction (STEMI; n=255-272). LVEDVi(indexed end-diastolic volume of LV) and LVESVi (indexed end-systolic volume of LV) were calculated from cardiac magnetic resonance imagingacquired in the acute phase and after 4 months. NT-proBNP, N-terminal pro-brain natriuretic peptide.Numbers are given as Spearman’s rho correlation coefficients. *p<0.05, **p<0.01.

Supplementary Table S2.Correlations between IL-1Ra and clinical variables.

IL-1Ra
Before PCI / IL-1Ra
After PCI / IL-1Ra
Day 1 / IL-1Ra
4 months / IL-1Ra
12 months
Infarctsize,acute / 0.06 / 0.001 / 0.06 / 0.02 / -0.07
Infarctsize, 4 months / 0.11 / 0.07 / 0.08 / 0.06 / 0.02
LVEF,acute / -0.12 / -0.07 / -0.14 / -0.03 / -0.01
LVEF, 4 months / -0.08 / -0.01 / -0.07 / -0.02 / -0.01
Area at risk / 0.08 / 0.06 / 0.07 / -0.01 / -0.04
Myocardialsalvage / -0.10 / 0.02 / -0.03 / -0.06 / 0.05
LVEDVi / 0.07 / 0.01 / 0.10 / -0.05 / -0.004
LVESVi / 0.006 / -0.04 / 0.12 / 0.008 / 0.08
Age / 0.06 / 0.10 / 0.07 / 0.10 / 0.02
BMI / 0.13 / 0.04 / 0.12 / 0.07 / 0.05
Peak troponin T / 0.11 / 0.08 / 0.10 / 0.02 / -0.05
Peak C-reactive protein / 0.20** / 0.18** / 0.35** / 0.11 / 0.11
Admission NT-proBNP / -0.04 / -0.01 / -0.02 / 0.14 / -0.02
Admission creatinine / 0.03 / 0.009 / 0.04 / -0.01 / -0.01
AdmissionHb / -0.02 / -0.06 / 0.002 / 0.000 / 0.06
Admission total cholesterol / -0.01 / -0.05 / 0.003 / 0.05 / 0.05
Fasting glucose / 0.08 / 0.03 / 0.16* / 0.07 / 0.10
HbA1c / 0.02 / 0.05 / 0.09 / 0.08 / 0.12
Time from symptom toPCI / 0.01 / -0.06 / -0.03 / 0.14* / 0.06

Correlations are based on plasma levels of interleukin-1 receptor antagonist (IL-1Ra) measured before and immediately after percutaneous coronary intervention (PCI), at Day 1 (median 18.3 hours after PCI) and at 4-month follow-up after ST-elevation myocardial infarction (n=255). LVEDVi(indexed end-diastolic volume of LV) and LVESVi (indexed end-systolic volume of LV) were calculated from cardiac magnetic resonance imagingacquired in the acute phase and after 4 months. Numbers are given as Spearman’s rho correlation coefficients. LVEF, left ventricular ejection fraction, NT-proBNP, N-terminal pro-brain natriuretic peptide.*p<0.05, **p<0.01.

Supplementary Table S3.Correlations between sIL-1R1 and clinical variables.

sIL-1R1
Before PCI / sIL-1R1
After PCI / sIL-1R1
Day 1 / sIL-1R1
4 months / sIL-1R1
1 year
Infarctsize,acute / -0.08 / 0.07 / 0.000 / -0.005 / 0.01
Infarctsize, 4 months / -0.11 / -0.004 / -0.02 / -0.03 / -0.01
EF,acute / -0.03 / -0.10 / -0.07 / -0.10 / 0.006
EF, 4 months / 0.03 / -0.08 / -0.06 / -0.06 / 0.02
Area at risk / -0.02 / 0.01 / -0.07 / -0.08 / -0.09
Myocardialsalvage / 0.06 / -0.01 / -0.06 / -0.09 / -0.04
LVEDVi / 0.02 / 0.07 / -0.02 / -0.07 / -0.08
LVESVi / -0.04 / -0.02 / -0.05 / -0.07 / -0.09
Age / 0.05 / -0.01 / 0.05 / 0.02 / -0.03
BMI / -0.03 / 0.01 / 0.12 / -0.001 / -0.04
Peak troponin T / -0.03 / 0.04 / 0.01 / 0.01 / 0.01
Peak C-reactive protein / 0.10 / 0.11 / 0.03 / -0.02 / -0.03
Admission NT-proBNP / 0.17* / 0.10 / 0.12 / 0.09 / 0.12
Admission creatinine / 0.12 / 0.06 / 0.09 / 0.004 / 0.06
AdmissionHb / 0.03 / 0.09 / 0.04 / 0.01 / 0.03
Admission total cholesterol / -0.01 / 0.09 / 0.02 / -0.05 / 0.01
Fasting glucose / -0.003 / 0.04 / 0.10 / -0.03 / -0.003
HbA1c / -0.04 / -0.04 / -0.02 / -0.12 / 0.05
Symptom-PCI time / -0.10 / -0.12 / -0.11 / -0.002 / 0.000

Correlations are based on plasma levels of soluble interleukin-1 receptor 1 (sIL-1R1) measured before and immediately after percutaneous coronary intervention (PCI), at Day 1 (median 18.3 hours after PCI) and at 4-month follow-up after ST-elevation myocardial infarction (n=255). LVEDVi(indexed end-diastolic volume of LV) and LVESVi (indexed end-systolic volume of LV) were calculated from cardiac magnetic resonance imagingacquired in the acute phase and after 4 months. LVEF, left ventricular ejection fraction, BMI, body mass index, NT-proBNP, N-terminal pro-brain natriuretic peptide.Numbers are given as Spearman’s rho correlation coefficients. *p<0.05.

Supplementary Table S4.Correlations between sIL-1R2 and clinical variables.

sIL-1R2
Before PCI / sIL-1R2
After PCI / sIL-1R2
Day 1 / sIL-1R2
4 months / sIL-1R2
1 year
Infarctsize,acute / 0.10 / 0.04 / 0.15* / 0.05 / 0.07
Infarctsize, 4 months / 0.08 / 0.03 / 0.09 / 0.06 / 0.09
LVEF,acute / -0.08 / -0.06 / -0.15* / -0.04 / -0.12
LVEF, 4 months / -0.17* / -0.08 / -0.12 / -0.07 / -0.08
Area at risk / 0.08 / 0.11 / 0.12 / 0.02 / 0.03
Myocardial salvage / -0.13 / -0.08 / -0.10 / -0.12 / -0.12
LVEDVi / 0.23** / 0.23** / 0.21** / 0.03 / 0.15*
LVESVi / 0.25** / 0.20* / 0.16* / 0.08 / 0.12
Age / -0.14* / -0.18** / -0.27** / -0.14* / -0.17**
BMI / 0.13* / 0.15* / 0.11 / -0.009 / -0.07
Peak Troponin T / 0.05 / -0.01 / 0.05 / 0.02 / 0.07
Peak CRP / 0.16* / 0.07 / 0.19** / 0.01 / 0.09
Admission NT-proBNP / -0.25** / -0.26** / -0.20** / -0.10 / -0.27**
Admission creatinine / 0.05 / 0.02 / 0.05 / 0.04 / 0.03
AdmissionHb / 0.21** / 0.21** / 0.17** / 0.07 / 0.10
Admission total cholesterol / 0.07 / 0.001 / 0.04 / 0.02 / 0.03
Fasting glucose / 0.16* / 0.12 / 0.17* / -0.01 / 0.03
HbA1c / 0.03 / 0.05 / 0.07 / -0.03 / -0.03
Symptom-PCI time / 0.005 / 0.04 / -0.06 / 0.07 / 0.07

Correlations are based on plasma levels of soluble interleukin-1 receptor 2 (sIL-1R2) measured before and immediately after percutaneous coronary intervention (PCI), at Day 1 (median 18.3 hours after PCI) and at 4-month follow-up after ST-elevation myocardial infarction (n=255). LVEDVi(indexed end-diastolic volume of LV) and LVESVi (indexed end-systolic volume of LV) were calculated from cardiac magnetic resonance imagingacquired in the acute phase and after 4 months. Numbers are given as Spearman’s rho correlation coefficients. *p<0.05, **p<0.01.

Supplementary Table S5.Correlations between IL-1RAcP and clinical variables.

IL-1RAcP
Before PCI / IL-1RAcP
After PCI / IL-1RAcP
Day 1 / IL-1RAcP
4 months / IL-1RAcP
1 year
Infarctsize,acute / -0.12 / -0.11 / -0.19** / -0.21** / -0.12
Infarctsize, 4 months / -0.14* / -0.15* / -0.17* / -0.20** / -0.13
LVEF,acute / 0.03 / 0.06 / 0.06 / 0.07 / 0.04
LVEF, 4 months / 0.08 / 0.08 / 0.10 / 0.11 / 0.08
Area at risk / -0.09 / 0.008 / -0.11 / -0.10 / -0.11
Myocardialsalvage / 0.16* / 0.12 / 0.09 / 0.10 / 0.14
LVEDVi / -0.02 / -0.01 / -0.04 / -0.10 / -0.08
LVESVi / -0.04 / -0.04 / -0.07 / -0.10 / -0.09
Age / 0.06 / -0.01 / 0.04 / 0.05 / -0.01
BMI / 0.05 / -0.06 / -0.01 / -0.03 / -0.08
Peak Troponin T / -0.11 / -0.16** / -0.17** / -0.20** / -0.14*
Peak CRP / -0.14* / -0.18** / -0.13 / -0.18** / -0.11
Admission NT-proBNP / 0.03 / 0.04 / -0.03 / -0.01 / 0.003
Admission creatinine / -0.03 / -0.05 / -0.03 / -0.01 / 0.02
AdmissionHb / -0.03 / 0.001 / -0.07 / -0.16** / -0.10
Admission total cholesterol / 0.12 / 0.19** / 0.14* / 0.06 / 0.06
Fasting glucose / 0.001 / -0.05 / -0.08 / -0.07 / -0.08
HbA1c / -0.06 / -0.09 / -0.05 / -0.05 / -0.04
Symptom-PCI time / -0.10 / -0.12 / -0.14* / -0.14* / -0.09

Correlations are based on plasma levels of soluble interleukin-1 receptor Accessory protein (sIL-1RAcP) measured before and immediately after percutaneous coronary intervention (PCI), at Day 1 (median 18.3 hours after PCI) and at 4-month follow-up after ST-elevation myocardial infarction (n=255). LVEDVi(indexed end-diastolic volume of LV) and LVESVi (indexed end-systolic volume of LV) were calculated from cardiac magnetic resonance imagingacquired in the acute phase and after 4 months. Numbers are given as Spearman’s rho correlation coefficients. *p<0.05, **p<0.01.

Supplementary Table S6.Univariable and multivariable linear regression analyses of associations between sIL-1R2and change in ΔLVEDVi.

Before PCI / After PCI / Day 1
Variable / β (95% CI) / p-value / β (95% CI) / p-value / β (95% CI) / p-value
Univariable analyses
sIL-1R2, per SD / 2.90 (0.74, 5.05) / 0.009 / 2.97 (0.84, 5.10) / 0.007 / 3.81 (1.65, 5.96) / 0.001
Age / -0.14 (-0.34, 0.06) / 0.16 / -0.14 (-0.34, 0.06) / 0.16 / -0.14(-0.34, 0.06) / 0.16
Male sex / 3.60 (-1.88, 9.08) / 0.20 / 3.60 (-1.88, 9.08) / 0.20 / 3.60 (-1.88, 9.08) / 0.20
Hypertension / 1.86 (-2.90, 6.62) / 0.44 / 1.86 (-2.90, 6.62) / 0.44 / 1.86 (-2.90, 6.62) / 0.44
Diabetes / 1.82 (-6.90, 10.55) / 0.68 / 1.82 (-6.90, 10.55) / 0.68 / 1.82 (-6.90, 10.55) / 0.68
Time from symptoms to PCI (ln), per SD / 1.91 (-0.20, 4.01) / 0.08 / 1.91 (-0.20, 4.01) / 0.08 / 1.91 (-0.20, 4.01) / 0.08
Anterior MI / 7.29 (3.17, 11.41) / 0.001 / 7.29 (3.17, 11.41) / 0.001 / 7.29 (3.17, 11.41) / 0.001
Peak TnT (In), per SD / 5.81 (3.85, 7.78) / <0.001 / 5.81 (3.85, 7.78) / <0.001 / 5.81 (3.85, 7.78) / <0.001
Peak CRP (ln), per SD / 6.11 (4.07, 8.16) / <0.001 / 6.11 (4.07, 8.16) / <0.001 / 6.11 (4.07, 8.16) / <0.001
NT-proBNP (ln), per SD / 1.86 (-0.35, 4.07) / 0.10 / 1.86 (-0.35, 4.07) / 0.10 / 1.86 (-0.35, 4.07) / 0.10
Admission Hb / 1.42 (0.07, 2.77) / 0.04 / 1.42 (0.07, 2.77) / 0.04 / 1.42 (0.07, 2.77) / 0.04
Ischemic post-conditioning / -1.78 (-6.01, 2.45) / 0.41 / -1.78(-6.01, 2.45) / 0.41 / -1.78 (-6.01, 2.45) / 0.41
Multivariablemodel 1
sIL-1R2, per SD / 3.01 (0.92, 5.09) / 0.005 / 2.96 (0.89, 5.02) / 0.005 / 3.94 (1.85, 6.02) / <0.001
Time from symptoms to PCI (ln), per SD / 2.21 (0.92, 5.09) / 0.04 / 2.18 (0.11, 4.24) / 0.04 / 2.48 (0.39, 4.57) / 0.02
Anterior MI / 7.70 (3.53, 11.87) / <0.001 / 7.54 (3.40, 11.67) / <0.001 / 7.47 (3.30, 11.63) / 0.001
Multivariablemodel 2
sIL-1R2, per SD / 2.29 (0.28, 4.29) / 0.03 / 3.12 (1.16, 5.08) / 0.001 / 3.22 (1.22, 5.21) / 0.002
Peak TnT (ln), per SD / 4.04 (1.79, 6.30) / <0.001 / 4.21 (1.99, 6.43) / <0.001 / 4.19 (1.96, 6.42) / <0.001
Peak CRP (ln), per SD / 3.89 (1.62, 6.17) / 0.001 / 4.05 (1.83, 6.26) / <0.001 / 3.64 (1.38, 5.90) / 0.001

Univariable and multivariable linear regression analyses of associations between sIL-1R2 measured before and after PCI and at day 1 after PCI and change in indexed left ventricular end-systolic volume (ΔLVEDVI, measured by CMR) from the acute phase to 4-month follow-up in 224 STEMI patients. Adjusted for clinical and biochemical covariates. Model 1: sIL-1R2, age, male sex, hypertension, diabetes mellitus, time from symptom to PCI, anterior MI, ischemic postconditioning. Model 2: model 1 + peak troponin T, peak CRP, admission NT-proBNP, admission hemoglobin.

Supplementary Table S7.Univariable and multivariable linear regression analyses of associations between sIL-1R2and change in ΔLVESVi.

Before PCI / After PCI / Day 1
Variable / β (95% CI) / p-value / β (95% CI) / p-value / β (95% CI) / p-value
Univariable analyses
sIL-1R2, per SD / 2.80 (0.93, 4.67) / 0.004 / 2.17 (0.30-4.04) / 0.02 / 2.82 (0.92-4.72) / 0.004
Age / -0.06 (-0.24, 0.11) / 0.48 / -0.06(-0.24, 0.11) / 0.48 / -0.06(-0.24, 0.11) / 0.48
Male sex / 0.94 (-3.86, 5.74) / 0.70 / 0.94(-3.86, 5.74) / 0.70 / 0.94(-3.86, 5.74) / 0.70
Hypertension / 0.34 (-3.83, 4.50) / 0.87 / 0.34(-3.83, 4.50) / 0.87 / 0.34(-3.83, 4.50) / 0.87
Diabetes / -2.86 (-10.46, 4.75) / 0.46 / -2.86 (-10.46, 4.75) / 0.46 / -2.86 (-10.46, 4.75) / 0.46
Time from symptoms to PCI (ln), per SD / 2.16 (0.34, 3.99) / 0.02 / 2.16 (0.34, 3.99) / 0.02 / 2.16 (0.34, 3.99) / 0.02
Anterior MI / 3.70 (0.04, 7.36) / 0.05 / 3.70 (0.04, 7.36) / 0.05 / 3.70 (0.04, 7.36) / 0.05
Peak TnT (In), per SD / 5.37 (3.66, 7.08) / <0.001 / 5.37 (3.66, 7.08) / <0.001 / 5.37 (3.66, 7.08) / <0.001
Peak CRP (ln), per SD / 5.04 (3.24, 6.84) / <0.001 / 5.04 (3.24, 6.84) / <0.001 / 5.04 (3.24, 6.84) / <0.001
Admission NT-proBNP (ln), per SD / 0.78 (-1.16, 2.72) / 0.43 / 0.78 (-1.16, 2.72) / 0.43 / 0.78 (-1.16, 2.72) / 0.43
Admission Hb / 0.81 (-0.38, 2.00) / 0.18 / 0.81(-0.38, 2.00) / 0.18 / 0.81(-0.38, 2.00) / 0.18
Ischemic post-conditioning / -1.54 (-5.22, 2.15) / 0.41 / -1.54 (-5.22, 2.15) / 0.41 / -1.54 (-5.22, 2.15) / 0.41
Multivariablemodel 1
sIL-1R2, per SD / 2.87 (1.04, 4.71) / 0.002 / 2.17 (0.33, 4.00) / 0.02 / 2.99 (1.13, 4.85) / 0.002
Time from symptoms to PCI (ln), per SD / 2.34 (0.5, 4.18) / 0.01 / 2.31 (0.47, 4.15) / 0.01 / 2.54 (0.67, 4.41) / 0.01
Anterior MI / 4.13 (0.45, 7.80) / 0.03 / 3.98 (0.30, 7.65) / 0.03 / 3.92 (0.21, 7.64) / 0.04
Multivariablemodel 2
sIL-1R2, per SD / 2.34 (0.59, 4.09) / 0.009 / 2.34 (0.61, 4.08) / 0.008 / 2.37 (0.61, 4.12) / 0.008
Peak TnT (ln), per SD / 4.00 (2.04, 5.96) / <0.001 / 4.08 (2.12, 6.05) / <0.001 / 4.06 (2.10, 6.03) / <0.001
Peak CRP (ln), per SD / 2.83 (0.85, 4.81) / 0.005 / 3.05 (1.09, 5.01) / 0.002 / 2.75 (0.77, 4.75) / 0.007

Univariable and multivariable linear regression analyses of the associations between sIL-1R2 measured before and after PCI and at day 1 after PCI and change in indexed left ventricular end-systolic volume (ΔLVESVI, measured by CMR) from the acute phase to 4-month follow-up in 224 STEMI patients. Adjusted for clinical and biochemical covariates. Model 1: sIL-1R2, age, male sex, hypertension, diabetes mellitus, time from symptom to PCI, anterior MI, ischemic postconditioning. Model 2: model 1 + peak troponin T, peak CRP, admission NT-proBNP, admission hemoglobin.

Supplementary Table S8.Univariable and multivariable linear regression analyses of associations between sIL-1R2and change in ΔLVEDVi.

ΔLVEDVi, sIL-1R2 Day 1.

Univariable analyses / β (95% CI) / P / R2
Peak CRP (ln), per SD / 6.11 (4.07, 8.16) / <0.001 / 0.14
sIL-1R2, per SD / 3.81 (1.65, 5.96) / 0.001 / 0.06
Multivariablemodel 3 / β (95% CI) / P / R2
Peak CRP (ln), per SD / 3.64 (1.38, 5.90) / <0.001 / 0.18
sIL-1R2, per SD / 3.22 (1.22, 5.21) / 0.005

Univariable and multivariable linear regression analyses of associations between sIL-1R2 measured at day 1 after PCI and change in indexed left ventricular end-diastolic volume (ΔLVEDVI, measured by CMR) from the acute phase to 4-month follow-up in 224 STEMI patients.

Supplementary Table S9.Univariable and multivariable linear regression analyses of associations between sIL-1R2and change in ΔLVESVi.

ΔLVESVi, sIL-1R2 Day 1.

Univariable analyses / β (95% CI) / P / R2
Peak CRP (ln), per SD / 5.04 (3.24, 6.84) / <0.001 / 0.13
sIL-1R2, per SD / 2.82 (0.92-4.72) / 0.004 / 0.04
Multivariablemodel 3 / β (95% CI) / P / R2
Peak CRP (ln), per SD / 3.64 (1.38, 5.90) / 0.001 / 0.15
sIL-1R2, per SD / 3.22 (1.22, 5.21) / 0.02

Univariable and multivariable linear regression analyses of associations between sIL-1R2 measured at day 1 after PCI and change in indexed left ventricular end-systolic volume (ΔLVESVI, measured by CMR) from the acute phase to 4-month follow-up in 224 STEMI patients.

Supplementary Table S10.Myocardial injury and function measured by CMR according to sIL-1RAcP values.

sIL-1RAcP before PCI / sIL-1RAcP after PCI / sIL-1RAcP day 1 / sIL-1RAcP 4 months
median /
median / P-value /
median /
median / P-value /
median /
median / P-value /
median /
median / P-value
CMR in acute phase
IS, %LV mass / 18.8 / 15.4 / 0.07 / 18.3 / 15.5 / 0.06 / 18.0 / 16.2 / 0.22
LVEF, % / 51 / 51 / 0.67 / 50 / 52 / 0.16 / 52 / 51 / 0.97
Area at risk, %LV / 43.1 / 40.4 / 0.24 / 41.3 / 43.4 / 0.76 / 42.7 / 42.0 / 0.30
MVO (presence) / 65 (58.6%) / 44 (42.3%) / 0.02 / 59 (54.1%) / 51 (45.9%) / 0.23 / 57 (54.8%) / 47 (43.9%) / 0.11
CMR after4 months
IS, %LV mass / 15.7 / 12.7 / 0.02 / 15.8 / 12.2 / 0.004 / 15.0 / 12.7 / 0.12 / 15.8 / 12.5 / 0.008
LVEF, % / 53 / 57 / 0.10 / 55 / 56 / 0.20 / 55 / 56 / 0.37 / 54 / 57 / 0.14
MS, % / 47.0 / 56.3 / 0.02 / 47.5 / 54.1 / 0.06 / 50.7 / 53.9 / 0.66 / 49.0 / 54.0 / 0.37
LVEDVi, mL/m2 / 4.9 / 3.9 / 0.37 / 4.9 / 4.3 / 0.60 / 3.0 / 4.9 / 0.68 / 4.8 / 4.3 / 0.07
LVESVi, mL/m2 / -0.9 / -1.8 / 0.47 / -0.9 / -1.0 / 0.74 / -2.1 / -0.7 / 0.78 / -0.7 / -1.3 / 0.09

Levels of sIL-1R2 were measured before and immediately after PCI, at Day 1 (median 18.3 hours after PCI) and at 4-months’ follow-up in 255 STEMI patients. Data are presented as median or numbers (%). P-values were determined by Mann-Whitney U test. CMR, cardiac magnetic resonance imaging; IS, infarct size; MS, myocardial salvage; LV, left ventricle; MVO, microvascular obstruction;LVEDVi, change in indexed LV end-diastolic volume; LVESVi, change in indexed LV end-systolic volume.